BioregulatorResearch
Vesugen
Also known as: Lys-Glu-Asp · KED
A Khavinson tripeptide for vascular intervention, restoring endothelial elasticity and reversing arterial hardening.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~30 minutes
Typical Dose
10 mg daily (oral, cycled)
Administration
Oral capsule
Mechanism of Action
Epigenetic modulation of endothelial cell gene expression, normalizing vascular tone and reversing atherosclerotic changes.
Key Research Areas
bioregulatorvascularendothelialcardiovascular
Frequently Asked Questions
What is Vesugen?▾
A Khavinson tripeptide for vascular intervention, restoring endothelial elasticity and reversing arterial hardening.
How does Vesugen work?▾
Epigenetic modulation of endothelial cell gene expression, normalizing vascular tone and reversing atherosclerotic changes.
What is the recommended dosage for Vesugen?▾
The typical research dosage is 10 mg daily (oral, cycled), administered via Oral capsule. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Vesugen?▾
The half-life of Vesugen is approximately ~30 minutes. This affects dosing frequency and timing in research protocols.
Is Vesugen FDA approved?▾
Vesugen is currently classified as "Research" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about Vesugen is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.